CalciMedica, Common Net Worth
CalciMedica, Common Net Worth Breakdown | CALC |
CalciMedica, Common Net Worth Analysis
CalciMedica, Common's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CalciMedica, Common's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CalciMedica, Common's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CalciMedica, Common's net worth analysis. One common approach is to calculate CalciMedica, Common's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CalciMedica, Common's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CalciMedica, Common's net worth. This approach calculates the present value of CalciMedica, Common's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CalciMedica, Common's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CalciMedica, Common's net worth. This involves comparing CalciMedica, Common's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CalciMedica, Common's net worth relative to its peers.
Enterprise Value |
|
To determine if CalciMedica, Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CalciMedica, Common's net worth research are outlined below:
| CalciMedica, Common generated a negative expected return over the last 90 days | |
| CalciMedica, Common has high historical volatility and very poor performance | |
| CalciMedica, Common has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (34.36 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CalciMedica, Common generates negative cash flow from operations | |
| About 17.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Insider Trading |
CalciMedica, Common uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CalciMedica, Common Stock. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CalciMedica, Common's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow CalciMedica, Common's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.66 M.Market Cap |
|
Project CalciMedica, Common's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.24) | (3.08) | |
| Return On Capital Employed | (3.08) | (2.93) | |
| Return On Assets | (3.24) | (3.08) | |
| Return On Equity | (4.84) | (4.60) |
When accessing CalciMedica, Common's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CalciMedica, Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CalciMedica, Common's profitability and make more informed investment decisions.
Please note, the presentation of CalciMedica, Common's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CalciMedica, Common's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CalciMedica, Common's management manipulating its earnings.
Evaluate CalciMedica, Common's management efficiency
CalciMedica, Common Stock has return on total asset (ROA) of (0.6492) % which means that it has lost $0.6492 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8376) %, meaning that it created substantial loss on money invested by shareholders. CalciMedica, Common's management efficiency ratios could be used to measure how well CalciMedica, Common manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -3.08. The current year's Return On Capital Employed is expected to grow to -2.93. As of January 20, 2025, Total Assets is expected to decline to about 10.4 M. In addition to that, Non Current Assets Total is expected to decline to about 495.9 K| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.09 | 1.98 | |
| Tangible Book Value Per Share | 2.09 | 1.98 | |
| Enterprise Value Over EBITDA | (0.19) | (0.20) | |
| Price Book Value Ratio | 1.42 | 1.49 | |
| Enterprise Value Multiple | (0.19) | (0.20) | |
| Price Fair Value | 1.42 | 1.49 | |
| Enterprise Value | -9.4 M | -8.9 M |
The decision-making processes within CalciMedica, Common are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CalciMedica, Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on CalciMedica, Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CalciMedica, Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CalciMedica, Common Corporate Filings
F3 | 16th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
| 13th of December 2024 Other Reports | ViewVerify |
CalciMedica, Common Earnings per Share Projection vs Actual
CalciMedica, Common Corporate Executives
Elected by the shareholders, the CalciMedica, Common's board of directors comprises two types of representatives: CalciMedica, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CalciMedica,. The board's role is to monitor CalciMedica, Common's management team and ensure that shareholders' interests are well served. CalciMedica, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CalciMedica, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth Stauderman | CoFounder Officer | Profile | |
| Stefan MD | CoFounder Advisor | Profile | |
| Patrick Hogan | CoFounder Advisor | Profile | |
| Anjana Rao | CoFounder Advisor | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CalciMedica, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CalciMedica, Common. If investors know CalciMedica, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CalciMedica, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CalciMedica, Common Stock is measured differently than its book value, which is the value of CalciMedica, that is recorded on the company's balance sheet. Investors also form their own opinion of CalciMedica, Common's value that differs from its market value or its book value, called intrinsic value, which is CalciMedica, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CalciMedica, Common's market value can be influenced by many factors that don't directly affect CalciMedica, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CalciMedica, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if CalciMedica, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CalciMedica, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.